Emily Adland

3.2k total citations
31 papers, 800 citations indexed

About

Emily Adland is a scholar working on Virology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Emily Adland has authored 31 papers receiving a total of 800 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Virology, 19 papers in Infectious Diseases and 12 papers in Epidemiology. Recurrent topics in Emily Adland's work include HIV Research and Treatment (22 papers), HIV/AIDS Research and Interventions (15 papers) and Immune Cell Function and Interaction (9 papers). Emily Adland is often cited by papers focused on HIV Research and Treatment (22 papers), HIV/AIDS Research and Interventions (15 papers) and Immune Cell Function and Interaction (9 papers). Emily Adland collaborates with scholars based in United Kingdom, South Africa and United States. Emily Adland's co-authors include Philip Goulder, Paul Klenerman, Philippa C. Matthews, Andrew Bell, W. Nicholas Haining, Claire Shannon‐Lowe, Henri‐Jacques Delecluse, Maximilian Muenchhoff, Alan B. Rickinson and Martin Rowe and has published in prestigious journals such as Proceedings of the National Academy of Sciences, PLoS ONE and Journal of Virology.

In The Last Decade

Emily Adland

30 papers receiving 795 citations

Peers

Emily Adland
Jonathan P. McNally United States
Emily Adland
Citations per year, relative to Emily Adland Emily Adland (= 1×) peers Jonathan P. McNally

Countries citing papers authored by Emily Adland

Since Specialization
Citations

This map shows the geographic impact of Emily Adland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily Adland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily Adland more than expected).

Fields of papers citing papers by Emily Adland

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emily Adland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily Adland. The network helps show where Emily Adland may publish in the future.

Co-authorship network of co-authors of Emily Adland

This figure shows the co-authorship network connecting the top 25 collaborators of Emily Adland. A scholar is included among the top collaborators of Emily Adland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily Adland. Emily Adland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
2.
Adland, Emily, Anna Csala, Nicholas Lim, et al.. (2023). Age- and sex-specific differences in immune responses to BNT162b2 COVID-19 and live-attenuated influenza vaccines in UK adolescents. Frontiers in Immunology. 14. 1248630–1248630. 6 indexed citations
3.
Vieira, Vinícius, et al.. (2022). Role of Early Life Cytotoxic T Lymphocyte and Natural Killer Cell Immunity in Paediatric HIV Cure/Remission in the Anti-Retroviral Therapy Era. Frontiers in Immunology. 13. 886562–886562. 5 indexed citations
4.
Adland, Emily, María C. Puertas, Thumbi Ndung’u, et al.. (2022). Next-generation point-of-care testing in pediatric human immunodeficiency virus infection facilitates diagnosis and monitoring of treatment. Medicine. 101(27). e29228–e29228.
5.
Martin, Geneviève, Debattama R. Sen, Matthew Pace, et al.. (2021). Epigenetic Features of HIV-Induced T-Cell Exhaustion Persist Despite Early Antiretroviral Therapy. Frontiers in Immunology. 12. 647688–647688. 18 indexed citations
6.
Roider, Julia, Maximilian Muenchhoff, Emily Adland, et al.. (2019). Increased Regulatory T-Cell Activity and Enhanced T-Cell Homeostatic Signaling in Slow Progressing HIV-infected Children. Frontiers in Immunology. 10. 213–213. 10 indexed citations
7.
Roider, Julia, J. Zachary Porterfield, Paul Ogongo, et al.. (2019). Plasma IL-5 but Not CXCL13 Correlates With Neutralization Breadth in HIV-Infected Children. Frontiers in Immunology. 10. 1497–1497. 4 indexed citations
8.
McNaughton, Anna, José Lourenço, Emily Adland, et al.. (2019). HBV vaccination and PMTCT as elimination tools in the presence of HIV: insights from a clinical cohort and dynamic model. BMC Medicine. 17(1). 43–43. 13 indexed citations
9.
Adland, Emily, Gerald Jesuthasan, Louise Downs, et al.. (2018). Hepatitis virus (HCV) diagnosis and access to treatment in a UK cohort. BMC Infectious Diseases. 18(1). 461–461. 19 indexed citations
10.
Roider, Julia, Takashi Maehara, Duran Ramsuran, et al.. (2018). High-Frequency, Functional HIV-Specific T-Follicular Helper and Regulatory Cells Are Present Within Germinal Centers in Children but Not Adults. Frontiers in Immunology. 9. 1975–1975. 19 indexed citations
11.
Adland, Emily, Luisa Mori, Anna Csala, et al.. (2018). Recovery of effective HIV-specific CD4+ T-cell activity following antiretroviral therapy in paediatric infection requires sustained suppression of viraemia. AIDS. 32(11). 1413–1422. 5 indexed citations
12.
Malik, Amna, Emily Adland, Henrik N. Kløverpris, et al.. (2017). Immunodominant cytomegalovirus-specific CD8+ T-cell responses in sub-Saharan African populations. PLoS ONE. 12(12). e0189612–e0189612. 8 indexed citations
13.
Tsai, Ming‐Han, Maximilian Muenchhoff, Emily Adland, et al.. (2016). Paediatric non-progression following grandmother-to-child HIV transmission. Retrovirology. 13(1). 65–65. 5 indexed citations
14.
Jooste, Pieter, Emily Adland, Samantha Daniel, et al.. (2016). Screening, characterisation and prevention of Hepatitis B virus (HBV) co-infection in HIV-positive children in South Africa. Journal of Clinical Virology. 85. 71–74. 16 indexed citations
15.
Mori, Masahiko, Emily Adland, P Paioni, et al.. (2015). Sex Differences in Antiretroviral Therapy Initiation in Pediatric HIV Infection. PLoS ONE. 10(7). e0131591–e0131591. 18 indexed citations
16.
Adland, Emily, Paul Klenerman, Philip Goulder, & Philippa C. Matthews. (2015). Ongoing burden of disease and mortality from HIV/CMV coinfection in Africa in the antiretroviral therapy era. Frontiers in Microbiology. 6. 1016–1016. 86 indexed citations
17.
Payne, Rebecca, Maximilian Muenchhoff, Jaclyn K. Mann, et al.. (2014). Impact of HLA-driven HIV adaptation on virulence in populations of high HIV seroprevalence. Proceedings of the National Academy of Sciences. 111(50). E5393–400. 62 indexed citations
18.
Muenchhoff, Maximilian, Emily Adland, Anna Carlqvist, et al.. (2014). Evaluation of the NucliSens EasyQ v2.0 Assay in Comparison with the Roche Amplicor v1.5 and the Roche CAP/CTM HIV-1 Test v2.0 in Quantification of C-Clade HIV-1 in Plasma. PLoS ONE. 9(8). e103983–e103983. 9 indexed citations
19.
Kløverpris, Henrik N., Emily Adland, Anette Stryhn, et al.. (2013). HIV Subtype Influences HLA-B*07:02-Associated HIV Disease Outcome. AIDS Research and Human Retroviruses. 30(5). 468–475. 16 indexed citations
20.
Adland, Emily, Jonathan M. Carlson, P Paioni, et al.. (2013). Nef-Specific CD8+ T Cell Responses Contribute to HIV-1 Immune Control. PLoS ONE. 8(9). e73117–e73117. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026